The clinical studies performed regarding the impact of anti-Nogo-A and anti-LINGO-1 in MS-related patients did not yield the promise that was expected, but additional studies and information regarding Nogo-A and LINGO-1 will support the interpretation and planning of future clinical trials aiming for more successful outcomes in the treatment of neurodegenerative diseases like MS. This evidence concerns the gene RTN4 and myeloid sarcoma.